A multi-faceted approach to the advancement of cell-based drug discovery By Dr Ralph J. Garippa Cell-based assays, particularly those involving the use of microscopic imaging, are undergoing a renaissance within many pharma and biotech drug development programmes. Much of this has to do with the licensing, partnering and… Read More
Label-Free Detection – New biosensors facilitate broader range of drug discovery applications By Dr John Comley This article highlights some of the findings of a recent market report on labelfree detection trends. In particular, it looks at the current perception, main use and biggest benefit of label-free detection… Read More
GENE EXPRESSION as a toxicological screening tool By Dr Bruce Seligmann The use of microarray data in drug development and requirements for FDA audit and approval. Toxicological safety testing of compounds has not yet advanced to the point where measurement of gene expression… Read More
Tissue Microarray (TMA) – A step ahead in drug discovery By Dr CR Camozzi Estimation of the clinical importance, market size and therapy-related side-effects are key questions in drug development. The ever-rising costs of drug discovery and development ($800-1,500 million for a successful drug research project) together with… Read More
The impact of early ADME profiling on drug discovery and development strategy By Dr Jianling Wang and Dr Laszlo Urban The increased costs in the discovery and development of new drugs, due in part to the high attrition rate of drug candidates in development, has led to… Read More
Functional screening of viral siRNA libraries in human primary cells By Dr Kara Bortone, Dr Frits Michiels, Dr Nick Vandeghinste, Dr Peter Tomme and Dr Helmuth van Es One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets… Read More
Novel concepts and therapeutic options for the treatment of schizophrenia By Dr Karoly Nikolich and Dr Roman Urfer Schizophrenia affects a large number of individuals irrespective of social status and education. Current treatments of schizophrenia represent the second largest central nervous system (CNS) pharmaceutical market, exceeding $12 billion… Read More
Metabonomics – A generic platform for the investigation of drug toxicity, altered gene function and disease processes By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry’s biggest problems attrition. This article discusses the scope and… Read More
Unlocking the value in Data By Dr Amber Salzman In recent years enormous sums have been spent on systems and data management, but are we getting full value from these investments? We discuss here how organisations, scientists and, indeed, vendors themselves must work as one to extract… Read More
By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in… Read More
Virtual Screening – Finding needles in a haystack on a shoestring By Dr David E. Clark, Neil V. Harris, Alan G. Roach and Dr Anthony D. Baxter In recent years, virtual screening (VS) has become an accepted approach to hit-finding alongside biochemical high-throughput screening (HTS). Large pharmaceutical companies… Read More
Share Share Tweet Email Tools for Structural Genomics – Accelerating the structure pipeline Tools for Structural Genomics – Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr… Read More
Opportunities for the pharmaceutical industry: key biotransformation technologies of the future By Praveen Kaul, Anirban Banerjee and Professor UC Banerjee Biotransformation is a broad and growing field of biotechnology and encompasses both enzymatic and microbial biocatalysis. Progress has been made in research on… Read More
Functional cell-based high throughput drug screening By Professor Daniel T. Chiu and Professor Owe Orwar Cell-based assays are poised to assume an increasingly important role in drug screening and discovery. It is becoming apparent that simple binding assays and in vitro experiments are grossly insufficient for extrapolating… Read More
Making the Most of Drug Discovery Data By Dr Nick Davies and Dr Tim Peakman Discovery scientists in most pharmaceutical companies are struggling with incompatible legacy systems, a growing volume of data and the imminent advent of a product model that will demand much more of them. Read More
Gene Expression: Analysis and Drug R&D By Dr Ralph Sinibaldi It is clear that gene expression profiling systems have a role to play in many facets of drug discovery and development, but several questions remain. We take a look at the use of DNA microarray for gene expression… Read More